Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 3/20 | 0.43 |
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | AOC1 | P19801 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.38 |
| ▸ | GABRR2 | P28476 | 1/20 | 0.38 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.38 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.38 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5164313 | 0.82 | TP53 (0.44) | TP53SMN1; SMN2NPC1RAB9AHRH3 | |
| SCHEMBL6670423 | 0.81 | HRH3 (0.42) | TP53SMN1; SMN2NPC1RAB9AHRH3 | |
| SCHEMBL5160606 | 0.80 | TP53 (0.41) | TP53SMN1; SMN2NPC1RAB9AHRH3 | |
| SCHEMBL19234747 | 0.79 | AOC1 (0.46) | TP53SMN1; SMN2NPC1RAB9AHRH3 | |
| SCHEMBL6664871 | 0.79 | AOC1 (0.42) | TP53SMN1; SMN2NPC1RAB9AHRH3 | |
| SCHEMBL10352986 | 0.78 | NPC1 (0.42) | TP53SMN1; SMN2NPC1RAB9AHRH3 | |
| SCHEMBL5163320 | 0.76 | AOC1 (0.43) | TP53SMN1; SMN2NPC1RAB9AHRH3 | |
| SCHEMBL890216 | 0.76 | — | — | |
| SCHEMBL26137400 | 0.75 | AOC1 (0.50) | TP53SMN1; SMN2NPC1RAB9AHRH3 | |
| SCHEMBL11033825 | 0.75 | GAA (0.51) | TP53SMN1; SMN2NPC1RAB9AHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 153 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1450795-A1 | PEPTIDE ISOSTERES CONTAINING A HETEROCYCLE USEFUL IN THE TREATMENT OF ALZHEIMER'S DISEASE | Elan Pharmaceuticals, Inc. (US) | 2004-09-01 | — | — | EP | claimed |
| WO-2003047576-A1 | PEPTIDE ISOSTERES CONTAINING A HETEROCYCLE USEFUL IN THE TREATMENT OF ALZHEIMER'S DISEASE | ELAN PHARMACEUTICALS, INC. (US) | 2003-06-12 | — | — | WO | claimed |
| EP-0603309-A1 | PEPTIDE ISOTERS CONTAINING A HETEROCYCLE AS H.I.V. INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1994-06-29 | — | — | EP | claimed |
| EP-3932919-B1 | JAK INHIBITOR COMPOUND AND USE THEREOF | HENAN MEDINNO PHARMACEUTICAL TECH CO LTD (CN) | 2024-06-26 | — | — | EP | disclosed |
| CN-117343063-A | Compounds as TRK inhibitors and/or RET inhibitors and uses thereof | 河南迈英诺医药科技有限公司 | 2024-01-05 | — | — | CN | disclosed |
| US-20230357199-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. | 2023-11-09 | — | — | US | disclosed |
| EP-3340983-B1 | ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF IMMUNE AND INFLAMMATORY DISORDERS | ACHILLION PHARMACEUTICALS INC (US) | 2023-10-04 | — | — | EP | disclosed |
| US-20230287005-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. | 2023-09-14 | — | — | US | disclosed |
| US-20230287005-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. | 2023-09-14 | — | — | US | disclosed |
| US-11718626-B2 | Macrocyclic compounds for treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2023-08-08 | — | — | US | disclosed |
| US-11708351-B2 | Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-20070299078-A1 | Quinoxalinyl Macrocyclic Hepatitis C Virus Serine Protease Inhibitors | ENANTA PHARMACEUTICALS, INC. | 2007-12-27 | — | — | US | disclosed |
| US-20070042952-A1 | Analogues of glp-1 | IPSEN PHARMA S.A.S. (FR) | 2007-02-22 | — | — | US | disclosed |
| US-20070042952-A1 | Analogues of glp-1 | IPSEN PHARMA S.A.S. (FR) | 2007-02-22 | — | — | US | disclosed |
| EP-1450795-A1 | PEPTIDE ISOSTERES CONTAINING A HETEROCYCLE USEFUL IN THE TREATMENT OF ALZHEIMER'S DISEASE | Elan Pharmaceuticals, Inc. (US) | 2004-09-01 | — | — | EP | disclosed |
| WO-2003047576-A1 | PEPTIDE ISOSTERES CONTAINING A HETEROCYCLE USEFUL IN THE TREATMENT OF ALZHEIMER'S DISEASE | ELAN PHARMACEUTICALS, INC. (US) | 2003-06-12 | — | — | WO | disclosed |
| EP-0603309-A1 | PEPTIDE ISOTERS CONTAINING A HETEROCYCLE AS H.I.V. INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1994-06-29 | — | — | EP | disclosed |
| WO-1993005026-A1 | PEPTIDE ISOTERS CONTAINING A HETEROCYCLE AS H.I.V. INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1993-03-18 | — | — | WO | disclosed |
| US-4717512-A | Preparation of acylated glycerophosphocholines and glycerophosphoethanolamines | CHEMIE LINZ AKTIENGESELLSCHAFT (AT) | 1988-01-05 | — | — | US | disclosed |
| US-4622180-A | Derivatives of glycerophosphocholine and glycerophosphoethanolamine, their preparation and their use | CHEMIE LINZ AKTIENGESELLSCHAFT (AT) | 1986-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230287005-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | CFD, F12, F3 | TP53 3869/4885SMN1; SMN2 2201/4885NPC1 1081/4885 |
| US-11718626-B2 | Macrocyclic compounds for treatment of medical disorders | CFD, TFPI, CFH | TP53 4507/4885SMN1; SMN2 2037/4885NPC1 245/4885 |
| US-20070042952-A1 | Analogues of glp-1 | GLP1R, IAPP, GIPR | TP53 3674/4885SMN1; SMN2 1262/4885NPC1 862/4885 |
| US-11708351-B2 | Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders | CFD, TFPI, CFH | TP53 4378/4885SMN1; SMN2 3485/4885NPC1 488/4885 |
| US-20230357199-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | CFD, TFPI, CFH | TP53 4378/4885SMN1; SMN2 3485/4885NPC1 488/4885 |
| US-20070299078-A1 | Quinoxalinyl Macrocyclic Hepatitis C Virus Serine Protease Inhibitors | PRSS1, SPINT2, CTSC | TP53 760/4885SMN1; SMN2 3674/4885NPC1 295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.